Anti-SF-25 monoclonal antibody
Alternative Names: Monoclonal antibody SF-25; SF-25Latest Information Update: 17 May 2018
Price :
$50 *
At a glance
- Originator Harvard University; Massachusetts General Hospital
- Developer Panacea Pharmaceuticals
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 16 May 2018 Panacea Pharmaceuticals is now called Sensei Biotherapeutics
- 26 Sep 2006 This programme is still in active development for cancer
- 17 Sep 2003 SF-25 has been licensed to Panacea worldwide